Search company, investor...

LJL Biosystems

Stage

Acquired | Acquired

Total Raised

$16.5M

Valuation

$0000 

About LJL Biosystems

LJL Biosystems, Inc. developed and manufactured automated instrumentation systems for clinical, research and drug development applications. The company was acquired by Molecular Devices Corporation (Nasdaq: MDCC) in August of 2000.

Headquarters Location

405 Tasman Drive

Sunnyvale, California, 94089,

United States

408-541-8787

Missing: LJL Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LJL Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

LJL Biosystems Patents

LJL Biosystems has filed 76 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/20/2015

7/20/2021

Electrophysiology, Membrane biology, Ion channels, Cell biology, Neurophysiology

Grant

Application Date

1/20/2015

Grant Date

7/20/2021

Title

Related Topics

Electrophysiology, Membrane biology, Ion channels, Cell biology, Neurophysiology

Status

Grant

Latest LJL Biosystems News

COMPANY NEWS; MOLECULAR DEVICES AGREES TO ACQUIRE LJL BIOSYSTEMS - The New York Times

May 10, 2022

COMPANY NEWS; MOLECULAR DEVICES AGREES TO ACQUIRE LJL BIOSYSTEMS Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. Give this article June 9, 2000, Section C, Page 4 Buy Reprints TimesMachine is an exclusive benefit for home delivery and digital subscribers. The Molecular Devices Corporation, a leading maker of systems used by the big drug companies in research and development, said yesterday that it would acquire LJL BioSystems in a $262.8 million stock swap. Both companies are based in Sunnyvale, Calif., and develop bioanalytical measurement systems that speed up and improve drug discovery research. Each share of LJL will be exchanged for three-tenths of a share of Molecular Devices. The ratio works out to about $17.72 per LJL share, based on the closing price on Wednesday. Shares of Molecular Devices were up $1.9375 each, at $61, in Nasdaq trading, where LJL gained $1.3125, to $17.5625. Advertisement

LJL Biosystems Frequently Asked Questions (FAQ)

  • Where is LJL Biosystems's headquarters?

    LJL Biosystems's headquarters is located at 405 Tasman Drive, Sunnyvale.

  • What is LJL Biosystems's latest funding round?

    LJL Biosystems's latest funding round is Acquired.

  • How much did LJL Biosystems raise?

    LJL Biosystems raised a total of $16.5M.

  • Who are the investors of LJL Biosystems?

    Investors of LJL Biosystems include Molecular Devices, Skyline Ventures, Bay City Capital, Edgemont Asset Management Co and Alta Partners.

  • Who are LJL Biosystems's competitors?

    Competitors of LJL Biosystems include CellChorus.

Compare LJL Biosystems to Competitors

S
Spatial Genomics

Spatial Genomics is a biology and life science technology company dedicated to empowering discovery. Spatial Genomics’ integrated technology platform consists of instrumentation, reagents, and software and is being developed with a vision of providing high multiplexity of multi-omic biological analysis capabilities. Its highly multiplexed spatial analysis technology will advance fundamental biology, precision medicine, drug, and biomarker discovery.

Singleron Logo
Singleron

Singleron is a developer of gene sequencing technology, focusing on massive and single-cell multi-omics analysis for drug development, scientific research, and genomics industries. The company develops a series of molecular diagnostic products and automation devices that can meet clinical applications.

Mission Bio Logo
Mission Bio

Mission Bio is developing technologies to analyze single cells within complex biological systems, revealing critical information not observable from bulk sample analysis. With proprietary microfluidic droplet technology, Mission Bio is developing research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology.

Celsius Therapeutics Logo
Celsius Therapeutics

Celsius Therapeutics applies a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover precision therapies that have an impact on the lives of patients with autoimmune diseases and cancer. By analyzing single cells, Celsius's approach has the potential to understand the causes of disease at an entirely new level of resolution that overcomes limitations of traditional genomic sequencing approaches.

C
CytoTronics

CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Its technology measures and manipulates live cells to produce high-resolution electrical and electrochemical cell-based assays. By providing single-cell resolution readouts, CytoTronics help enhance the accuracy of cell-biology information. The company was founded in 2020 and is based in Boston, Massachusetts.

Vizgen Logo
Vizgen

Vizgen is developing the next generation of spatially resolved genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. MERFISH provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.